Green light for stem cell-based Parkinson’s study

The Swedish Medical Products Agency has approved an application from a consortium of research institutions, which includes Lund University, to initiate a clinical phase I and a phase IIa study in Parkinsons disease, STEM-PD. The aim is to investigate whether transplanted nerve cells, which form dopamine and are generated from embryonic stem cells, can replace the nerve cells that are destroyed at disease onset. Thus begins another clinical trial in this neurodegenerative chronic disease that, after 105 years after its discovery, still lacks curative treatments.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/11/green-light-for-stem-cell-based-parkinsons-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/